1 |
Osteoporose bei Patienten unter Therapie mit Vitamin K-AntagonistenLiebig, Stephanie. January 2006 (has links)
Universiẗat, Diss., 2006--Giessen.
|
2 |
Osteoporose bei Patienten unter Therapie mit Vitamin-K-AntagonistenLiebig, Stephanie January 1900 (has links) (PDF)
Zugl.: Giessen, Univ., Diss., 2006
|
3 |
Är NOAK ett bättre behandlingsalternativ än warfarin vid förmaksflimmer?Leksell, Sofia January 2016 (has links)
Bakgrund Förmaksflimmer är en arytmi som uppkommer av att sinusknutan slutar styra hjärtrytmen och impulser initieras istället på flera olika ställen i förmaken. Detta orsakar en snabb och oregelbunden kontraktion med försämrad cirkulation som resultat. Förmaksflimmer är den vanligaste orsaken till stroke och en viktig del i behandlingen av förmaksflimmer är därför att förebygga stroke genom antikoagulerande läkemedel. Warfarin har länge varit förstahandsval, men nya läkemedel, så kallade icke vitamin K antagonist oral antikoagulantia (NOAK) har de senaste åren godkänts som förebyggande behandling vid indikationen förmaksflimmer. Syftet med arbetet var att undersöka effekt, blödningsrisk och kostnad av NOAK som förebyggande behandling av stroke och systemisk emboli hos patienter med förmaksflimmer. Metod och material Arbetet utfördes som en litteraturstudie där fem kliniska studier från databasen PubMed analyserades. I fyra studier jämfördes de tre faktor Xa-hämmarna apixaban, edoxaban och rivaroxaban, samt trombinhämmaren dabigatran med warfarin. I en studie jämfördes apixaban med Aspirin®. Resultat Alla NOAK visades reducera risken att drabbas av stroke och emboli minst likvärdigt med warfarin. Dabigatran 150 mg och edoxaban 60 mg visades även vara effektivare än warfarin (RR=0,66; P<0,001, respektive RK=0,79; P<0,001). Apixaban reducerade risken för stroke och systemisk emboli med mer än 50 % i jämförelse med Aspirin® (RK= 0,45; P<0,001). Uppkomst av större blödning var likvärdigt förekommande i jämförelse mellan NOAK och warfarin. Dabigatran 110 mg, edoxaban 30 mg, edoxaban 60 mg och apixaban 5 mg visade på lägre risk för större blödning. Apixaban och Aspirin® visades vara likvärdiga avseende uppkomst av större blödning. Slutsats Icke vitamin K antagonist oral antikoagulantia är effektiva som förebyggande behandling av stroke och emboli hos patienter med förmaksflimmer, med lägre blödningsrisk än warfarin, men till en högre kostnad. / Atrial fibrillation is an arrhythmia characterized by rapid and uncontrolled contraction of the atria. The irregular contractions leads to incomplete circulation, accumulation of blood in the atria and increases the risk of stroke and embolism. An important part in the treatment of atrial fibrillation is to prevent the risk of stroke by use of anticoagulants. The first line treatment is the vitamin K antagonist warfarin. The drug has many side effects such as risk of bleeding, difficulties to adjust the dose and interactions with both drugs and food. In recent years, new drugs, called non vitamin K antagonist oral anticoagulants (NOAC), have been approved as preventive treatment of stroke in patients with atrial fibrillation. These include three factor Xa inhibitors: apixaban, rivaroxaban, and edoxaban, and one thrombin inhibitor: dabigatran. In this study, the efficacy, risk of bleeding and cost of NOAK was investigated for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The study was conducted as a literature study where five clinical trials from the database PubMed was analyzed. In four studies, the three factor Xa inhibitors apixaban, edoxaban and rivaroxaban, and the thrombin inhibitor dabigatran were compared with warfarin. In one study apixaban was compared with Aspirin®. In all studies the prevention of stroke and systemic embolism and risk of bleeding was investigated. All NOAC reduced the risk of stroke and embolism at least equal to warfarin. Dabigatran 150 mg and edoxaban 60 mg was also more effective than warfarin. Apixaban reduced the risk of stroke and systemic embolism with more than 50 % compared with aspirin. The occurrence of major bleeding was similar in comparison of Dabigatran 150 mg, respectively rivaroxaban 20 mg and warfarin. Dabigatran 110 mg, edoxaban 30 mg, edoxaban 60 mg and apixaban 5 mg showed a lower risk of major bleeding than warfarin. Apixaban and Aspirin® appeared to be equivalent regarding the occurrence of major bleeding. Non Vitamin K antagonist oral anticoagulants are effective in the prevention of stroke and embolism in patients with atrial fibrillation, with lower risk of bleeding than warfarin, but with a higher cost.
|
4 |
Investigating methods of improving the safety of oral anticoagulation with computer assisted dosage and standardisation of the International Normalised RatioIbrahim, Saied January 2015 (has links)
This thesis combines five published research papers investigating methods of improving the safety and control of oral anticoagulation, with the use of computer assisted dosage and the standardisation of the International Normalised Ratio (INR). The INR is a conventional measurement derived from the time it takes blood of a patient to form a clot and is used to monitor the effects of widely used oral anticoagulants such as warfarin for the prevention of stroke and other related disorders. The first paper investigates whether the use of computer-assisted programs was as safe and effective as medical staff manual dosage in the prevention of bleeding or thrombotic complications during oral anticoagulant treatment. This was an international multi-centre randomised study conducted by the European Action on Anticoagulation (EAA) investigating the clinical benefit of two computer programs, PARMA 5 (Italy) and DAWN AC (UK). Composite clinical events were reduced by 7.6% using computer programs, though not achieving statistical significance (p=0.1), showing computer programs to be not dissimilar to medical staff dosage. The second paper recommends guidelines for screening safety and effectiveness of other marketed computer programs based on the results of the EAA study. A process for a candidate computer program to achieve non-inferiority relative to the medical staff dosage arm from the EAA study is explained. The third paper introduces a modified approach to the 'Direct INR' method for the standardisation of INR termed the 'Prothrombin Time/INR Line' (PT/INR). This was directly compared to the local International Sensitivity Index (ISI) calibration procedure originally approved by the World Health Organisation and later by the United States Food and Drug Administration (FDA). Using manually certified lyophilised plasmas tested by specialist centres, the PT/INR Line using a set of 5 calibrant plasmas to establish a fitted line to estimate local INR was shown to be as effective as the FDA procedure. The fourth paper investigates the PT/INR Line further by using simulated sets of calibrant plasmas across the therapeutic range of 2.0-4.5 INR and determining the PT/INR Line. Local INR of five validation plasmas, certified by 3 centres using the manual PT technique, was determined using the estimated PT/INR Lines and compared with local ISI calibration. Using 4 or 5 calibrant plasmas to determine the PT/INR Line was shown to be as accurate as local ISI calibrations for reliable local INR.The fifth and final paper assessed INR variability and control in oral anticoagulant therapy using a method termed the Variance Growth Rate (VGR), and compared its predictive ability of adverse events with the Time in Target INR range (TIR), the conventional method used in evaluating the quality of oral anticoagulant therapy. The VGR method was shown to be a better predictor of adverse bleeding or thrombotic episodes in the short term period prior to an event (3 and 6 months) compared with TIR.
|
5 |
Adherence to INR monitoring in the community among VKA-treated patients in Saskatchewan : an observational study2014 November 1900 (has links)
Background:
Vitamin-K antagonists (VKA) are a class of oral anticoagulant medications used to prevent blood clots. The anticoagulant intensity of VKAs is measured with a blood test known as the International Normalized Ratio (INR). Traditionally, international guidelines have recommended INR tests every 4 weeks for all patients. However, adherence to these guidelines has never been investigated in real world settings. The objectives of this study were to describe adherence to INR testing in Saskatchewan among patients receiving VKA medications, and to identify predictors of optimal adherence.
Methods:
This was a retrospective cohort study of VKA users in Saskatchewan captured in the administrative data between 2003 and 2010. Physician claims for anticoagulation monitoring were used as a proxy for INR testing. Adherence to INR testing was measured using the Continuous, Multiple-Interval Measure of Medication Gaps (CMG). Individuals were considered adherent if adherence by the CMG was at least 80%. Hierarchical (random effects) logistic regression models were developed to identify important predictors of optimal INR monitoring. Individual physician identification was considered a random effect in these models. The dependent variable was the achievement of optimal adherence, defined as ≥80% adherence to the 4-week test interval.
Results:
Among 17,388 VKA users, 42% resided in rural areas and virtually all (99%) were monitored by a general practitioner. During a median follow-up of 514 days, 50% of patients exhibited at least 74% adherence to INR testing if a 4-week interval was used as the reference standard. However, the estimated median adherence increased dramatically to 98% when the benchmark for optimal testing was lengthened to every 12 weeks. The most prominent risk factors for poor adherence to INR monitoring appeared to be rural residence (rural vs. urban OR 0.55, 95% CI 0.47-0.64 among subjects age ≥75 years) and duration of VKA therapy (≥731 vs. 35-90 days OR 0.04, 95% CI 0.03-0.05).
Discussion:
Adherence to INR testing appeared to be acceptable for most VKA-treated patients in Saskatchewan. However, this data indicated that adherence might be more problematic in the subgroup of rural residents. Possible explanations include reduced access to testing facilities or the shortage of physicians in rural areas. Further research is required to understand if poor access is the underlying cause of non-adherence to INR testing in the rural population.
|
6 |
Prevalence of drug-drug interactions of warfarin prescriptions in South Africa / Stephanie BlaauwBlaauw, Stephanie January 2012 (has links)
Background: Warfarin is an anticoagulant that is used for the prophylactic and therapeutic
treatment for a wide range of thrombo-embolic disorders. The prescribing and monitoring of
warfarin therapy is challenging due to the fact that warfarin exhibits numerous interactions
with other drugs and a variety of factors that influence the dosing of warfarin.
Objective: The general objective of this study was to investigate the prevalence of drugs
prescribed with warfarin that may have a potential drug-drug interaction (DDI) with warfarin.
Methods: This was a cross-sectional, observational or qualitative study that was conducted
on medicine claims data of a pharmaceutical benefit management company for patients
receiving warfarin therapy for a six year period, ranging from 1 January 2005 to 31
December 2010. Drug products that were co-prescribed with warfarin were also identified
from the medicine claims database. The total number of prescriptions for all drug products
during the study period were analysed and compared to the warfarin dataset. This was done
by means of the SAS 9.1® computer package (SAS Institute, 2004). The total number of
prescriptions and medicine items claimed from the database during the study period were
respectively 49 523 818 and 118 305 941. Potential DDls between warfarin and coprescribed
drugs were identified and classified according to a clinically significant rating. The
clinically significance ratings of potential DDls are described in three degrees of severity,
identified as major, moderate and minor (Tatro, 2011 :xiv).
Results: The database consisted of 427 238 warfarin prescriptions and 427 744 warfarin
medicine items, which represented 0.9% of the total number of prescriptions and 0.4% of
total number of medicine items. The total number of patients who claimed warfarin
prescriptions through the database represented 0.9% (n=68 575) of the total number of
patients who claimed prescriptions in the total database (2005-2010). General practitioners
prescribed the highest frequency of warfarin medicine items, representing 58.3%
(n=249 202) of the total number prescribed. The age group that claimed the highest frequency of warfarin prescriptions (n=327 592, 76.6%) and the highest frequency of
warfarin medicine items (n=327 984, 76.7%) was age group 4 (consisting of patients 59
years and older). The distribution between females and males regarding warfarin
prescriptions claimed (n=205 999, 48.2%; n=221 117, 51.8%) and warfarin medicine items
claimed (n=206 232, 48.2%; n=221 390, 51.8%) were almost equal. General practitioners
prescribed the highest average PDD (7.01 mg ± 9.86 mg) of warfarin medicine items.
Paediatric cardiologists prescribed the lowest average PDD (4.61 mg ± 1.29 mg) of warfarin
medicine items. A d-value of 0.1 indicates that there is no practical difference of the average
PDD between general practitioners and paediatric cardiologists. The average PDD of
warfarin medicine items between females (6.60 mg ± 9.06 mg) and males (6.74 mg± 8.41
mg) was almost equal. The age group who was prescribed the highest average PDD was
age group 2 (consisting of patients 20 years to 39 years old) (7.42 mg± 7.42 mg). Age group
4 (consisting of patients 59 years and older) (6.50 mg± 8.90 mg) was prescribed the lowest
average PDD of warfarin medicine items. A d-value of 0.1 indicates that there is no practical
difference of the average PDDs of warfarin medicine items between these two age groups.
The results revealed that drugs with a significance rating (SR) of 1 (n=155 066, 43.3%), 2
(n=30128, 8.4%), 4 (n=137144, 38.3%), and 5 (n=36144, 10.1%) were co-prescribed with
warfarin in the six year study period. The five drugs that was co-prescribed with warfarin
most frequently was aspirin (n=48 903, 13.6%), thyroxine (n=33 954, 9.5%), amiodarone
(n=25 056, 7.0%), simvastatin (n=19 070, 5.3%) and celecoxib (n=10 794, 3.0%). These five
drugs have a SR of 1.
Conclusions: This study showed that the top five drugs most frequently prescribed with
warfarin are aspirin, thyroxine, amiodarone, simvastatin and celecoxib. These drugs can
potentially interact with warfarin. The potential interactions of these drugs are rated with a
significance rating of 1. This concludes that drugs that can potentially cause life threatening
effects and permanent damage are commonly co-prescribed with warfarin. Clinical data
concerning the INR or PT must be obtained in order to evaluate whether or not warfarin
therapy is changed when a potentially interacting drug is co-prescribed. The age of the
patients as well as the duration of warfarin treatment should also be obtained in order to
assess whether warfarin treatment is changed with the progression of age. / MPharm (Pharmacy Practice), North-West University, Potchefstroom Campus, 2013
|
7 |
Prevalence of drug-drug interactions of warfarin prescriptions in South Africa / Stephanie BlaauwBlaauw, Stephanie January 2012 (has links)
Background: Warfarin is an anticoagulant that is used for the prophylactic and therapeutic
treatment for a wide range of thrombo-embolic disorders. The prescribing and monitoring of
warfarin therapy is challenging due to the fact that warfarin exhibits numerous interactions
with other drugs and a variety of factors that influence the dosing of warfarin.
Objective: The general objective of this study was to investigate the prevalence of drugs
prescribed with warfarin that may have a potential drug-drug interaction (DDI) with warfarin.
Methods: This was a cross-sectional, observational or qualitative study that was conducted
on medicine claims data of a pharmaceutical benefit management company for patients
receiving warfarin therapy for a six year period, ranging from 1 January 2005 to 31
December 2010. Drug products that were co-prescribed with warfarin were also identified
from the medicine claims database. The total number of prescriptions for all drug products
during the study period were analysed and compared to the warfarin dataset. This was done
by means of the SAS 9.1® computer package (SAS Institute, 2004). The total number of
prescriptions and medicine items claimed from the database during the study period were
respectively 49 523 818 and 118 305 941. Potential DDls between warfarin and coprescribed
drugs were identified and classified according to a clinically significant rating. The
clinically significance ratings of potential DDls are described in three degrees of severity,
identified as major, moderate and minor (Tatro, 2011 :xiv).
Results: The database consisted of 427 238 warfarin prescriptions and 427 744 warfarin
medicine items, which represented 0.9% of the total number of prescriptions and 0.4% of
total number of medicine items. The total number of patients who claimed warfarin
prescriptions through the database represented 0.9% (n=68 575) of the total number of
patients who claimed prescriptions in the total database (2005-2010). General practitioners
prescribed the highest frequency of warfarin medicine items, representing 58.3%
(n=249 202) of the total number prescribed. The age group that claimed the highest frequency of warfarin prescriptions (n=327 592, 76.6%) and the highest frequency of
warfarin medicine items (n=327 984, 76.7%) was age group 4 (consisting of patients 59
years and older). The distribution between females and males regarding warfarin
prescriptions claimed (n=205 999, 48.2%; n=221 117, 51.8%) and warfarin medicine items
claimed (n=206 232, 48.2%; n=221 390, 51.8%) were almost equal. General practitioners
prescribed the highest average PDD (7.01 mg ± 9.86 mg) of warfarin medicine items.
Paediatric cardiologists prescribed the lowest average PDD (4.61 mg ± 1.29 mg) of warfarin
medicine items. A d-value of 0.1 indicates that there is no practical difference of the average
PDD between general practitioners and paediatric cardiologists. The average PDD of
warfarin medicine items between females (6.60 mg ± 9.06 mg) and males (6.74 mg± 8.41
mg) was almost equal. The age group who was prescribed the highest average PDD was
age group 2 (consisting of patients 20 years to 39 years old) (7.42 mg± 7.42 mg). Age group
4 (consisting of patients 59 years and older) (6.50 mg± 8.90 mg) was prescribed the lowest
average PDD of warfarin medicine items. A d-value of 0.1 indicates that there is no practical
difference of the average PDDs of warfarin medicine items between these two age groups.
The results revealed that drugs with a significance rating (SR) of 1 (n=155 066, 43.3%), 2
(n=30128, 8.4%), 4 (n=137144, 38.3%), and 5 (n=36144, 10.1%) were co-prescribed with
warfarin in the six year study period. The five drugs that was co-prescribed with warfarin
most frequently was aspirin (n=48 903, 13.6%), thyroxine (n=33 954, 9.5%), amiodarone
(n=25 056, 7.0%), simvastatin (n=19 070, 5.3%) and celecoxib (n=10 794, 3.0%). These five
drugs have a SR of 1.
Conclusions: This study showed that the top five drugs most frequently prescribed with
warfarin are aspirin, thyroxine, amiodarone, simvastatin and celecoxib. These drugs can
potentially interact with warfarin. The potential interactions of these drugs are rated with a
significance rating of 1. This concludes that drugs that can potentially cause life threatening
effects and permanent damage are commonly co-prescribed with warfarin. Clinical data
concerning the INR or PT must be obtained in order to evaluate whether or not warfarin
therapy is changed when a potentially interacting drug is co-prescribed. The age of the
patients as well as the duration of warfarin treatment should also be obtained in order to
assess whether warfarin treatment is changed with the progression of age. / MPharm (Pharmacy Practice), North-West University, Potchefstroom Campus, 2013
|
Page generated in 0.0991 seconds